Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who did buy 352.232 on friday?.
Yes, with our mate Tom Cruise Sta. Loose. He worked in Dime years ago.
2 or 3 years more. Who knows!!!
DiMi,,nice close today!!
$DiMi
And who is selling these shares?. The company is buying but who is selling?.
Today $1.
Tomorrow will begin the delisting.
Next week 0,8.
1,18 now
Q is coming.
Trades = red red and red
1,20 now. Do you have something to stop that?.
Great Q in few time....PPHMQ
Ok. We are in the best company. Do you thing?.
But we are 1.30. Do not?.
I told you 1.25 on yesterday. Wrong!!!.
Now 1.25. Close 1.10 or 1.
Out of nasdaq in a few time.
Peregrine Pharmaceuticals, Inc. (PPHM) was formed more than 30 years ago and has never been profitable. Their lead asset, bavituximab, has been in development since 2005; 735 patients have been treated in 16 trials and there is currently no visible path to registration. Despite the doom and gloom, Peregrine's top five executives feel justified in rewarding themselves with nearly $3MM/year in compensation; so much for pay for performance.
Bavituximab, a first-in-class phosphatidylserine-targeting chimeric antibody (having mouse and human components), is the centerpiece of Peregrine's pipeline. Phosphatidylserine (PS) is a phospholipid that is expressed on the surface of many cancer cells and cells undergoing apoptosis making it a logical target for cancer therapy.
Clinical development of bavituximab for the treatment of cancer began in 2008. Since that time, Peregrine has conducted twelve Phase-I/-II studies and treated 613 cancer patients but has yet to observe a statistically significant improvement over a contemporary standard-of-care (SOC).
Lung Cancer
Peregrine initiated a randomized Phase-II study of docetaxel ± bavituximab in 2nd-line NSCLC patients (N=121) in 2010. The results of the study were the subject of a recent press release in which the company reported that the "results from this Phase-II trial indicate a meaningful improvement in median overall survival of 11.7 months in the 3mg/kg bavituximab plus docetaxel arm compared to 7.3 months in the control arm (HR=0.73; p value=0.217)." To add to the hype, the company went on to say that "these compelling results strongly support advancing the 3mg/kg bavituximab plus docetaxel combination into Phase-III development in second-line NSCLC." To be clear, this was a failed trial (P = 0.217), the results were not compelling and the "improvement" in median overall survival was orders of magnitude away from achieving statistical significance. This was, in part, due to the inclusion of a 1 mg/kg dose arm which reduced the size of each arm to 40 patients. Given that there was a significant volume of data available for docetaxel in combination with 3mg/kg of bavituximab at the time this study was initiated, there was no apparent reason to include the 1mg/kg arm.
Peregrine Pharmaceuticals' Bavituximab: It's Time To Throw In The Towel
1.10 today.
Black Tuesday
The company will close.
Black monday....helppppp
Manipulation.
The y will get we lose our money.
1,20 tiday
Sure wont
Every body are selling. Not good news.
They are the winners and we are the loosers.
We will not get our money back.
No way
You do not understand pacience is the mother of the science?.
Pacience is the mother of the science.
O do not like this situation.
No way. 1.75 PM
So bad. After hours 1,68
Today from 2,59 to 1,76
Another black day again. -18%
He is Aladin's friend
Yes, with ATRNQ
Go down sure.
But not on monday like all the weeks.
Red red loose your red
Cocktails and dreams....Tom Cruise.
What will happen on feb 11th?.
We are lost all our money and Dr. P said it was a great company to invest.
He said the same like here.
I didnt bought today. Uffff
Thanks Dr. P